JP2009542608A5 - - Google Patents

Info

Publication number
JP2009542608A5
JP2009542608A5 JP2009517403A JP2009517403A JP2009542608A5 JP 2009542608 A5 JP2009542608 A5 JP 2009542608A5 JP 2009517403 A JP2009517403 A JP 2009517403A JP 2009517403 A JP2009517403 A JP 2009517403A JP 2009542608 A5 JP2009542608 A5 JP 2009542608A5
Authority
JP
Japan
Prior art keywords
acid
compound
group
optionally
aurora
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542608A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2007/002428 external-priority patent/WO2008001101A2/en
Publication of JP2009542608A publication Critical patent/JP2009542608A/ja
Publication of JP2009542608A5 publication Critical patent/JP2009542608A5/ja
Pending legal-status Critical Current

Links

JP2009517403A 2006-06-29 2007-06-29 医薬組合せ剤 Pending JP2009542608A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80621306P 2006-06-29 2006-06-29
PCT/GB2007/002428 WO2008001101A2 (en) 2006-06-29 2007-06-29 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
JP2009542608A JP2009542608A (ja) 2009-12-03
JP2009542608A5 true JP2009542608A5 (https=) 2011-09-08

Family

ID=38698851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517403A Pending JP2009542608A (ja) 2006-06-29 2007-06-29 医薬組合せ剤

Country Status (4)

Country Link
US (1) US20110159111A1 (https=)
EP (1) EP2043635A2 (https=)
JP (1) JP2009542608A (https=)
WO (1) WO2008001101A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
EP1833819A1 (en) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
US8404718B2 (en) * 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
EP2049119A2 (en) * 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
GEP20125574B (en) 2008-01-11 2012-07-10 Glenmark Pharmaceuticals Sa Fused pyrimidine derivatives as trpv3 modulators
WO2009138799A1 (en) * 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
US8318928B2 (en) 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
CN102241973B (zh) * 2011-05-04 2014-06-25 宁波大学 一种具有绿色发光性能的荧光材料及其制备方法
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN102329610B (zh) * 2011-09-23 2013-07-10 宁波大学 一种紫色荧光材料及其制备方法
US20130150426A1 (en) * 2011-11-22 2013-06-13 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US8895611B1 (en) 2013-07-17 2014-11-25 King Fahd University Of Petroleum And Minerals Cytotoxic compounds for treating cancer
EP3313392B1 (en) 2015-06-23 2020-09-16 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
DK3380086T3 (da) 2015-11-25 2021-11-22 Io Therapeutics Inc Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
RU2758669C2 (ru) * 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
CN115626935B (zh) 2016-10-03 2025-07-15 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
CN110382707A (zh) 2017-02-27 2019-10-25 詹森药业有限公司 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途
CN110494434B (zh) * 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
US12083192B2 (en) * 2017-12-04 2024-09-10 Actinium Pharmaceuticals, Inc. Methods for treatment of patients with myelodysplastic syndromes
IL275129B2 (en) 2017-12-08 2023-10-01 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
CN112022848B (zh) * 2020-08-13 2022-02-22 中南大学湘雅二医院 索拉非尼在治疗1型糖尿病中的应用
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
CN117562907B (zh) * 2023-11-17 2025-08-22 广州医科大学 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE251141T1 (de) * 1995-03-10 2003-10-15 Berlex Lab Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
DK0906279T3 (da) * 1996-05-30 2003-02-03 Hoffmann La Roche Pyrrolderivater
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
SI1194425T1 (sl) * 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
DE10108480A1 (de) * 2001-02-22 2002-09-05 Bayer Ag Pyrazolylpyrimidine
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US20040242559A1 (en) * 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
GB0315657D0 (en) * 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PL2256106T3 (pl) * 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
US7932281B2 (en) * 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
EP1833819A1 (en) * 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
KR20070107707A (ko) * 2005-01-21 2007-11-07 아스텍스 테라퓨틱스 리미티드 피라졸 키나제 억제제와 추가 항종양제의 조합물
EP1899299B1 (en) * 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
EP2049119A2 (en) * 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
JP5528807B2 (ja) * 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US20080132223A1 (en) * 2006-12-04 2008-06-05 Chun-Fu Lin Systems and methods for providing traffic information

Similar Documents

Publication Publication Date Title
JP2009542608A5 (https=)
JP2009542610A5 (https=)
ES2965468T3 (es) Compuestos heterocíclicos para uso en el tratamiento del cáncer
EP2678336B1 (en) Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
CN107922388B (zh) 用于抑制shp2活性的化合物和组合物
EP2997030B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
CN107108637B (zh) 三唑并嘧啶化合物及其用途
CN106170288B (zh) 药物化合物
RU2437885C2 (ru) Производные дигидропиразолопиримидинона
JP2021522275A (ja) サイクリン依存性キナーゼ阻害剤としての２−アミノ−ピリジンまたは２−アミノ−ピリミジン誘導体
CN109970708B (zh) 大麻素受体调节剂
CN107207531B (zh) 作为TGF-β抑制剂的稠合的咪唑衍生物
KR20230090318A (ko) 헬리오스의 피페리디닐 소분자 분해 및 사용 방법들
PT2727918T (pt) Compostos e composições como inibidores de proteína quinase
MX2014014110A (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
TW200845990A (en) Heterocyclic compounds with CXCR3 antagonist activity
BR112019024114A2 (pt) Composto, e, métodos de modulação de uma resposta imune e de profilaxia ou tratamento de uma condição
TW202313048A (zh) 組合療法
JP2012518598A (ja) ピリミドピリミドインダゾール誘導体
CN112313220B (zh) Pd-l1拮抗剂化合物
KR102926889B1 (ko) Cdk8/19 저해제
WO2020198067A1 (en) Pkm2 modulators and methods for their use
EP3397632B1 (en) 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
TW202400578A (zh) 新穎的化合物及其用於抑制檢查點激酶２的用途
EP4466265A1 (en) Deoxycytidine kinase inhibitors